PHARMACY PRICING SUIT SETTLEMENT ENSURES PRICING POLICY CHANGES WITHOUT INJUNCTION, PLAINTIFF LEAD LAWYERS MAINTAIN; FTC INVESTIGATING INDUSTRY PRICING
The proposed $409 mil. settlement in pharmacy's class action antitrust lawsuit is sufficient to ensure that manufacturers will alter pricing practices that produced the litigation without an injunction, plaintiffs' attorney Michael Freed of the Chicago firm Much Shelist Freed Denenberg Ament Bell & Rubenstein told Chicago federal court Judge Charles Kocoras at a fairness hearing on the settlement March 27.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth